Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
about
Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysisNicotine addictionNicotine receptors and depression: revisiting and revising the cholinergic hypothesisOrthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking CessationVarenicline and cardiovascular adverse events: a perspective reviewCardiovascular effects of pharmacologic therapies for smoking cessationSerotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorderPreclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotypeIntersubunit Bridge Formation Governs Agonist Efficacy at Nicotinic Acetylcholine 4 2 Receptors: UNIQUE ROLE OF HALOGEN BONDING REVEALEDAn Inventory of Methods for the Assessment of Additive Increased Addictiveness of Tobacco ProductsMechanisms of inhibition and potentiation of α4β2 nicotinic acetylcholine receptors by members of the Ly6 protein familyVarenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized TrialRemoving obstacles in neuroscience drug discovery: the future path for animal models.Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research.Treatment of nicotine addiction: present therapeutic options and pipeline developments.Substance abuse, memory, and post-traumatic stress disorderCellular, molecular, and genetic substrates underlying the impact of nicotine on learning.Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, studyGalantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report.Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements.Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neuronsModulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice.Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.Beta2 subunit containing acetylcholine receptors mediate nicotine withdrawal deficits in the acquisition of contextual fear conditioning.Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nicotine.Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists: scheduled-controlled responding and hypothermia in C57BL/6J mice.Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.Comparison of the reinforcing properties of nicotine and cigarette smoke extract in ratsStructural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptorsVarenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence.Open label smoking cessation with varenicline is associated with decreased glutamate levels and functional changes in anterior cingulate cortex: preliminary findings.Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes.Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.Dissociable effect of acute varenicline on tonic versus cue-provoked craving in non-treatment-motivated heavy smokers.Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens.The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement.Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior.
P2860
Q21254640-E6D7E1A8-4DF3-46FA-8A9F-543594AB170FQ24626554-E0A9A636-0EBE-484D-A6A3-7C7830200C15Q24634536-287D099B-3F80-423F-BCB8-D7F362982BACQ26774830-AD21E2C8-BF01-4D53-BBF1-56D4709C4F36Q26830506-F1B7C12B-6A59-4897-888F-C00227FECF6BQ26849379-60F36585-C55B-41C3-BF55-B1582338D0F5Q27015917-3AA44746-186B-4AE4-A6B5-FA7C7D269B7BQ27021772-69D6F338-96DE-4868-98A8-1575CE53E11FQ27676179-6A51188E-E375-4B92-A014-7E9935EB2506Q28075342-1163BBB9-A9FB-42C7-A185-8AFB68821352Q28509139-7F98E4D4-F81A-4084-A41F-055CF5C95A2EQ28552053-C928E9B1-A934-46D1-94F9-ECFC85E4EB6BQ28755229-ABC7A96D-0732-4CEB-8BFD-82F26C8BDAE5Q30244252-A4DD4EDE-780D-4D07-9703-E1C42840591EQ30398847-56550C02-B074-417E-9DBC-74CC56D54616Q30407985-56B27C4C-5A72-4102-9656-E1738A74AC10Q30422037-12188323-E932-4309-B25D-76262635FB93Q30443702-BD3E2091-3799-4A16-9195-7C9BDC1E3563Q30446699-417FEEBB-F18E-463D-AF3D-6C87CEDB0A23Q30454909-3A93C791-63C2-410B-8812-7D61924B9C51Q30455599-9B57240E-98DE-4430-ABD7-40AA4D1D821CQ30461965-A8729EEE-E8A9-465D-87C6-03CF46C28CF3Q30467200-5A0463C2-7598-4296-BEF4-7D1C201C5BEAQ30475871-FE8D02EE-6021-4241-98FD-C3083374AC1AQ30487079-DCF36E34-BEFB-47B6-9A43-ABA0E3E26E0EQ30491573-AD5B74EB-6F9A-4233-9A84-37A2D221E294Q30493138-22E04D82-B8B4-4E86-A612-12EB0C0BC041Q30502320-24E19E3B-042C-41FA-B212-8BEA43C196DDQ30724397-0D781DE1-477E-4C4B-8820-5D0D2503B845Q33582051-4CA6D52D-FE09-4B39-9D2E-6CE7D2C59AA8Q33764231-78CC8B55-50E8-42B8-A8DE-167D5DA62E70Q33770793-19F03A07-E2FE-49F1-9D11-A2E369508ECFQ33824199-75933743-7FBA-45BF-85DE-20EC4490D513Q33859178-8920F8F9-27BC-4070-A4B4-6D3D31B745BBQ33861982-4C6CB2D9-DB42-4266-9BA1-49737E43025CQ33870433-360FA2A9-81CB-4F6A-8197-082326A1CCA9Q33903788-0C013990-7BEF-475D-985E-FF17A78BA82EQ33929766-01F35E63-6AC9-43D8-88C7-188D552A1E1DQ33943158-6A2777F1-330C-43B9-8115-68F07617EE5CQ34035211-0BCDDC22-C511-444B-8E41-EEF18DA4CA85
P2860
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pharmacological profile of the ...... ffective smoking cessation aid
@ast
Pharmacological profile of the ...... ffective smoking cessation aid
@en
Pharmacological profile of the ...... ffective smoking cessation aid
@nl
type
label
Pharmacological profile of the ...... ffective smoking cessation aid
@ast
Pharmacological profile of the ...... ffective smoking cessation aid
@en
Pharmacological profile of the ...... ffective smoking cessation aid
@nl
prefLabel
Pharmacological profile of the ...... ffective smoking cessation aid
@ast
Pharmacological profile of the ...... ffective smoking cessation aid
@en
Pharmacological profile of the ...... ffective smoking cessation aid
@nl
P2093
P921
P3181
P1433
P1476
Pharmacological profile of the ...... ffective smoking cessation aid
@en
P2093
C C Rovetti
D W Schulz
E Schaeffer
F D Tingley
K E Williams
L K Chambers
P304
P3181
P356
10.1016/J.NEUROPHARM.2006.10.016
P407
P577
2007-03-01T00:00:00Z